Aurobindo uses patent pool for generic AIDS drugs
LONDON (Reuters) - Aurobindo Pharma has become the first major generic drugmaker to join a patent pool designed to make HIV/AIDS treatments more widely available to the poor, paving the way for it to sell cheap medicines in many countries.
The Medicines Patent Pool said on Tuesday the agreement would allow Aurobindo to make a range of AIDS drugs licensed to the pool by Gilead Sciences, the leading maker of HIV drugs, in July.
Aurobindo has also elected to take advantage of a key provision in the pool's licences in order to sell one drug, tenofovir, to a wide range of countries without paying royalties. These could include several middle-income countries such as Argentina, Brazil, Chile, Colombia, Malaysia, the Philippines, Ukraine and Uruguay.
Around 33 million people worldwide have the human immunodeficiency virus (HIV) that causes AIDS. Most live in Africa and Asia, where medicines have to be very cheap to allow those who need them to be able to afford them.
The Medicines Patent Pool, launched by the UNITAID health financing system that is funded by a tax on airline tickets, aims to address the problem by creating a system for patent holders to license technology to makers of cheap generics.
(Reporting by Ben Hirschler; Editing by David Holmes)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- India Inc happy with Modi, but holding back on investment: poll
- Modi to launch plan for every Indian household to have bank account
- U.S. seeks coalition against Islamic State, but military partners no sure bet
- Modi eyes breakthrough nuclear pact on Japan trip
India is hoping to win Japanese backing for a nuclear energy pact during a visit by Prime Minister Narendra Modi, and lure investment into its $85 billion market while addressing Japan's concern about nuclear proliferation. Full Article